Life Biosciences announced Sunday that it has dosed the first participant in its Phase I clinical trial of partial cellular reprogramming therapy, marking a pivotal milestone for the Boston-based longevity startup. The trial, conducted at a partner clinical site in the Greater Boston area, follows the company's disclosure of an $80 million funding round led by prominent biotech investors earlier this week.
The therapy, grounded in Nobel Prize-winning research on induced pluripotent stem cells and advanced through years of work by Harvard professor David Sinclair and his collaborators, aims to partially reverse epigenetic aging markers in targeted tissues without pushing cells into a fully undifferentiated state. The company has described the approach as 'resetting the biological clock' at the cellular level, a concept that has generated significant scientific debate as well as investor enthusiasm.
Chief Executive Officer Mehmood Khan confirmed in a statement that the Phase I study will initially enroll 24 participants aged 55 to 75, monitoring safety, tolerability, and early biomarker signals over a six-month observation period. 'Today represents the translation of a decade of laboratory science into a genuine clinical intervention,' Khan said. 'Our first obligation is safety, and we have designed this trial with that principle at its core.'
The announcement is likely to intensify scrutiny from regulatory scientists and bioethicists who have cautioned that reprogramming technologies carry theoretical risks of aberrant cell growth. The FDA granted Life Biosciences an Investigational New Drug clearance following an extended review process that required additional pre-clinical safety data submitted last autumn.
Industry analysts noted that the timing of the trial initiation, immediately following the funding close, signals confidence from the company's board that manufacturing and regulatory conditions are sufficiently de-risked. Competitors including Altos Labs and Retro Biosciences are expected to respond with updates on their own pipeline timelines as the cellular rejuvenation field enters its first clinical phase.